No effect of enalapril on progression in autosomal dominant polycystic kidney disease

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2314-2320

  van Dijk, Marjan A ^a   Breuning, Martijn H ^a   Duiser, Rik ^a   van Es, Leendert A ^a   Westendorp, Rudi G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ACE inhibition; ADPKD; GFR; Progression; Randomized trial

Indexed keywords

ALBUMIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INULIN; PLACEBO;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INULIN CLEARANCE; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATENOLOL; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 0242320297     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg417     Document Type: Article

References (19)

1. Gonzalo A, Gallego A, Tato A et al. Age at renal replacement therapy in autosomal dominant polycystic kidney disease. Nephron 1996; 74: 620
2. Gabow PA, Johnson AM, Kaehny WD et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992; 41: 1311-1319
3. Chapman AB, Johnson AM, Gabow PA et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5: 1349-1354
4. Bjorck S, Nyberg G, Mulec H et al. Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471
5. Maschio G, Cagnoli L, Claroni F et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicenter, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 265-269
6. Harrap SB, Davies DL, Macnicol AM et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991; 40: 501-508
7. Barrett BJ, Foley R, Morgan J et al. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994; 46: 1118-1123
8. Watson ML, Macnicol AM, Allan PL et al. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 1992; 41: 206-210
9. Torres VE, Berndt TJ, Okamura M et al. Mechanisms affecting the development of renal cystic disease induced by diphenylthiazole. Kidney Int 1988; 33: 1130-1139
10. McEwan PE, Gray GA, Sherry L et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis. Circulation 1998; 98: 2765-2773
11. Keith DS, Torres VE, Johnson CM et al. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 1994; 24: 491-498
12. Ravine D, Gibsron RN, Walker RG et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-827
13. Franz KA, Reubi FC. Rate of functional deterioration in polycystic kidney disease. Kidney Int 1983; 23: 526-529
14. Hateboer N, Van Dijk MA, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 1999; 353: 103-107
15. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945
16. Klahr S, Breyer JA, Beck GJ et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2037-2047
17. Ecder T, Edelstein ChL, Fick-Brosnahan GM et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001; 21: 98-103
18. Marin R, Ruilope LM, Aljana P et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertension 2001; 19: 1871-1876
19. Ruggenenti P, Perna A, Gherardi G et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000; 35: 1155-1165